The role of tissue factor pathway inhibitor-2 in cancer biology

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 7, 2007, Pages 653-659

  Sierko, Ewa ^a,b   Wojtukiewicz, Marek Z ^a,b   Kisiel, Walter ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Regional Comprehensive Cancer Center in Bialystok   (Poland)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Coagulation inhibitors; TFPI 2

Indexed keywords

APROTININ; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 8A; CHYMOTRYPSIN; KALLIKREIN; MESSENGER RNA; PLACENTA PROTEIN 5; PLASMIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRYPSIN;

CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CPG ISLAND; EPIGENETICS; HEMOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

APOPTOSIS; CHROMOSOMES, HUMAN, PAIR 7; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GLYCOPROTEINS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SERINE PROTEINASE INHIBITORS;

EID: 36349029749     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991532     Document Type: Review

References (97)

1. Sprecher CA, Kisiel W, Mathews S, Foster DC. Molecular cloning, expression, and partial characterization of a second tissue-factor-pathway- inhibitor. Proc Natl Acad Sci USA 1994;91:3353-3357
2. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-93
3. Peterson LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996;35:266-272
4. Chand HS, Schmidt AE, Bajaj SP, Kisiel W. Structure-function analysis of the reactive site in the first Kunitz-type domain of human factor pathway inhibitor-2. J Biol Chem 2004;279:17500-17507
5. Kisiel W, Sprecher CA, Foster DC. Evidence that a second tissue factor pathway inhibitor (TFPI-2) and placental protein 5 are equivalent. Blood 1994;84:4384-4385
6. Bohn H, Winckler W. Isolierung und Charakterisierung des Plazenta-Proteins PP5. Arch Gynaek 1977;223:179-186
7. Rao CN, Liu YY, Peavey CL, Woodley DT. Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys 1995;317:311-314
8. Rao CN, Peavey CL, Liu YY, Lapiere JC, Woodley DT. Partial characterization of matrix-associated serine protease inhibitors from human skin cells. J Invest Dermatol 1995;104:379-383
9. Rao CN, Reddy P, Liu Y, et al. Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys 1996;335:82-92
10. Siiteri JE, Koistinen HAT, Salem HAT, Bohn H, Seppaelae M. Placental protein 5 is related to blood coagulation and fibrinolytic systems. Life Sci 1982;30:1885-1891
11. Meisser A, Bischof P, Bohn H. Placental protein 5 (PP5) inhibits thrombin-induced coagulation of fibrinogen. Arch Gynecol 1985;236:197-201
12. Miyagi Y, Koshikawa N, Yasumitsu H, et al. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem (Tokyo) 1994;116:939-942
13. Miyagi Y, Yasumitsu H, Eki T, et al. Assignment of the human PP5/TFPI-2 gene to 7q22 by FISH and PCR-based human/rodent cell hybrid mapping panel analysis. Genomics 1996;35:267-268
14. Kamei S, Kazama Y, Foster DC, Kisiel W. Genomic structure and promoter activity of the human tissue factor pathway inhibitor-2 gene. Biochim Biophys Acta 2001;1517:430-435
15. Hubé F, Reverdiau P, Iochmann S, Cherpi-Antar C, Gruel Y. Characterization and functional analysis of TFPI-2 gene promoter in a human choriocarcinoma cell line. Thromb Res 2003;109:207-215
16. Iino M, Foster DC, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol 1998; 18:40-46
17. Ortego J, Escribano J, Coca-Prados M. Gene expression of proteases and proteases inhibitors in the human ciliary epithelium and ODM-2 cells. Exp Eye Res 1997;65:289-299
18. Udagawa K, Miyagi Y, Hirahara F, et al. Specific expression of PP5/TFPI-2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta 1998;19:217-223
19. Buetzow R, Virtanen I, Seppaelae M, et al. Monoclonal antibodies reacting with placental protein 5: use in radioimmunoassay, Western blot analysis, and immunohistochemistry. J Lab Clin Med 1988;111:249-256
20. Wahlstroem T, Bohn H, Seppaelae M. Immunohistochemical demonstration of placental protein 5 (PP5) - like material in the seminal vesicles and the ampullar part of vas deferens. Life Sci 1982;31:2723-2725
21. Wojtukiewicz MZ, Sierko E, Zimnoch L, Kozłowski L, Sulkowski S, Kisiel W. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 2003;90:140-146
22. Ranta T, Siiteri JE, Koistinen R, et al. Human seminal plasma contains a protein that shares physiochemical and immunochemical properties with placental protein 5 from the human placenta. J Clin Endocrinol Metab 1981;53:1087-1089
23. Seppaelae M, Tenhunen A, Koskimies AI, Wahlstroem T, Koistinen R, Stenmam UH. Hyperstimulated human preovulatory follicular fluid contains placental protein 5 (PP5). Fertil Steril 1984;41:62-65
24. Rao CN, Lakka SS, Kin Y, et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 2001;7:570-576
25. Izumi H, Takahashi C, Oh J, Noda M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogene. FEBS Lett 2000;481:31-36
26. Rollin J, Régina S, Vourc'h P, et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007;56:273-280
27. Rollin J, Iochmann S, Bléchet C, et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005;92:775-783
28. Sato N, Parker AR, Fukushima N, et al. Epigenetic inactivation of TFPI-2 as a mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005;24:850-858
29. Wong CM, Ng YL, Lee JM, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007;45:1129-1138
30. Osella P, Carlson A, Wyandt H, Milunsky A. Cytogenetic studies of eight squamous cell carcinomas of the head and neck. Deletion of 7q, a possible primary chromosomal event. Cancer Genet Cytogenet 1992;59:73-78
31. Atkin NB, Baker MC. Chromosome 7q deletions: observations on 13 malignant tumors. Cancer Genet Cytogenet 1993;67:123-125
32. Rowley JD, Mitelman F. Principles of molecular cell biology of cancer: chromosome abnormalities in human cancer and leukemia. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. 4th ed. Philadelphia, PA: JB Lippincott; 1993:67-91
33. Saito E, Okamoto A, Saito M, et al. Genes associated with the genesis of leiomyoma of the uterus in a commonly deleted chromosomal region at 7q22. Oncol Rep 2005;13:2386-2397
34. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001;20:171-193
35. Sell SM, Tullis C, Stracner D, Song CY, Gewin J. Minimal interwal defined on 7q in uterine leiomyoma. Cancer Genet Cytogenet 2005;157:67-69
36. Konduri SD, Osman FA, Rao CN, et al. Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas. Oncogene 2002;21:921-928
37. Konduri SD, Yanamandra N, Dinh DH, et al. Physiological and chemical inducers of tissue factor pathway inhibitor-2 in human glioma cells. Int J Oncol 2003;22:1277-1283
38. Nobeyama Y, Okochi-Takada E, Furuta J, et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 2007;121:301-307
39. Steiner FA, Hong JA, Fischette MR, et al. Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 2005;23:2386-2397
40. Konduri SD, Srivenugopal KS, Yanamandra N, et al. Promoter methylation and silencind of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human gliomas cells. Oncogene 2003;22:4509-4516
41. Jiang P, Watanabe H, Okada G, et al. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic carcinoma. Cancer Sci 2006;97:1267-1272
42. Rao CN, Segawa T, Navari JR, et al. Methylation of TFPI-2 gene is not the sole cause of its silencing. Int J Oncol 2003;22:843-848
43. Kast C, Wang M, Whiteway M. The ERK/MAPK pathway regulates the activity of the human tissue factor pathway inhibitor-2 promoter. J Biol Chem 2003;278:6787-6794
44. Khosravi-Far R, Campbell S, Rossman KL, Der CJ. Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv Cancer Res 1998;72:57-107
45. Shapiro P. Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy. Crit Rev Clin Lab Sci 2002;39:285-330
46. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997;99:1478-1483
47. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-4187
48. Kempaiah P, Chand HS, Kisiel W. Identification of a human TFPI-2 slice variant that is upregulated in human tumor tissue. Mol Cancer 2007;6:20-31
49. Torres-Collado AX, Kisiel W, Iruela-Arispe ML, Rodriguez-Manzaneque JC. ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2. J Biol Chem 2006;28:17827-17837
50. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:621-628
51. Jin M, Udagawa K, Miyagi E, et al. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 2001;83:325-333
52. Lakka SS, Konduri SD, Mohanam S, Nicolson GL, Rao JS. In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2. Clin Exp Metastasis 2000;18:239-244
53. Konduri SD, Rao CN, Chandrasekar N, et al. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene 2001;20:6938-6945
54. Rao CN, Cook B, Liu Y, et al. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer 1998;76:749-756
55. Konduri SD, Tasiou A, Chandrasekar N, Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro. Int J Cancer 2001;18:127-131
56. Konduri SD, Tasiou A, Chandrasekar N, Nicolson GL, Rao JS. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis 2000;18:303-308
57. Carroll V, Binder B. The role of the plasminogen activation system in cancer. Semin Thromb Hemost 1999;25:183-197
58. Siiteri JE, Koistinen HAT, Salem HAT, Bohn H, Seppaelae M. Placental protein 5 is related to blood coagulation and fibrinolytic systems. Life Sci 1982;30:1885-1891
59. Rao CN, Mohanam S, Puppala A, Rao JS. Regulation of pro-MMP-1 and pro-MMP-3 activation by tissue factor pathway inhibitor-2/matrix associated serine protease inhibitor. Biochem Biophys Res Commun 1999;255:94-98
60. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001;107:1117-1126
61. Du X, Chand HS, Kisiel W. Human tissue factor pathway inhibitor-2 does not bind or inhibit activated matrix metalloproteinase-1. Biochim Biophys Acta 2003;162:242-245
62. Kondraganti S, Gondi CS, Gujrati M, et al. Restoration of tissue factor patway inhibitor inhibits invasion and trumor growth in vitro and in vivo a malignant meningioma cell line. Int J Oncol 2006;29:25-32
63. Sun Y, Xie M, Liu M, Jin D, Li P. Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2. Laryngoscope 2006;116:596-601
64. Neaud V, Hisaka T, Monvoisin A, et al. Paradoxical proinvasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells. J Biol Chem 2000;275:35565-35569
65. Tasiou A, Konduri SD, Yanamandra N, et al. A novel role of tissue factor pathway inhibitor-2 in apoptosis of malignant human gliomas. Int J Cancer 2001;19:591-597
66. George J, Gondi CS, Dinh DH, Gujrati M, Rao JS. Restoration of tissue factor patway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res 2007;13:3507-3517
67. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992;18:104-116
68. Hillen HFP. Thrombosis in cancer patients. Ann Oncol 2000;11(Suppl. 3):273-276
69. Wojtukiewicz MZ, Rucinska M, Zacharski RR, et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 2001;86:1416-1420
70. Wojtukiewicz MZ, Rucińska M, Zimnoch L, et al. Expression of prothrombin fragment 1 + 2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000;97:335-342
71. Shoji M, Hancock WW, Abe K, et al. Activation of blood coagulation and angiogenesis in cancer. Am J Pathol 1998;152:399-411
72. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Indirect activation of blood coagulation in colon cancer. Thromb Haemost 1989;62:1062-1066
73. Wojtukiewicz MZ, Zacharski LR, Rucińska M, et al. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost 1999;82:1659-1662
74. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990;10:579-582
75. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990;65:481-485
76. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990;93:516-521
77. Wojtukiewicz MZ, Tang TG, Ben-Josef E, Renaud C, Walz DA, Honn KV. Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 1995;55:698-704
78. Wojtukiewicz MZ, Tang TG, Ciarelli JJ, et al. Thrombin increases the metastatic potential of tumor cell. Int J Cancer 1993;54:793-806
79. Wojtukiewicz MZ, Tang TG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased αIIbβ3 expression on the cell surface. Thromb Res 1992;68:233-245
80. Even-Ram S, Uziely B. Cohen P met al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4:909-914
81. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27-31
82. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992;11:249-266
83. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. J Biol Chem 1999;274:23969-23976
84. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-1327
85. Neaud V, Duplantier JG, Mazzocco C, Kisiel W. Thrombin up-regulates tissue factor pathway inhibitor-2 synthesis through a cyclogenase-2-dependent, epidermal growth factor receptor-independent mechanism. J Biol Chem 2004;279:5200-5206
86. Yanamandra N, Kondraganti S, Gondi CS, et al. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer 2005;115:998-1005
87. Ivanciu L, Gerard RD, Tang H, Lupu F, Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol 2007;27:310-316
88. Xu Z, Maiti D, Kisiel W, Duh EL. Tissue factor pathway inhibitor-2 is up-regulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:2819-2825
89. Ruf W, Seftor E, Petrovan RJ, et al. Differential role of tissue factor pathway inhibitor 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003;63:5381-5389
90. Liu C, Huang H, Donate F, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 2002;62:560-566
91. Shirakawa K, Tsuda H, Heike Y, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001;61:445-451
92. Pezzella F. Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Lancet 2000;355:1787-1800
93. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001;158:1279-1288
94. Sharma N, Seftor REB, Seftor EA, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 2002;50:189-201
95. Passalidou E, Trivella M, Singh N, et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 2002;86:244-249
96. Ruf W, Seftor EA, Petrovan RJ, et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003;63:5381-5389
97. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999;25:173-182